Our portfolio company Mekonos has formally closed its US$4.6mil capital raise, led by Novartis with participation from a number of US institutional VC Funds as well as Matū Fund. The…
Andressen Horowitz has produced an interesting podcast episode about the recent Nobel Prize in Chemistry awarded to two researchers behind CRISPR, exploring When, Who, How, and What Now. They look…
Emmanuelle Charpentier and Jennifer Doudna have been awarded the Nobel Prize for Chemistry for their work on developing CRISPR, the revolutionary gene editing technology that allows scientists to cut and…
Vijay Pande and Andy Tran from Andressen Horowitz have penned a piece about the top 16 open problems that they can see in engineering biology, particularly in the pharma space.…
A recent update from Vas Narasimhan, the CEO of Novartis, tells a story of how digital technologies are revolutionising healthcare, and how they are trying to accelerate progress through their…
The University of California Office of Innovation and Entrepreneurship has released a really great, accessible article about Mekonos, one of our portfolio companies. It details the journey that the team…
The world's largest pharmaceutical company, Novartis, has signalled their intent to move away from expensive manufacturing and towards new disruptive technologies like Crispr and CAR-T. While this means job losses…